In a release dated September 29, 2016, the securities watchdog charged Robin Gadimian, who was a former senior director of regulatory affairs at the company, as having made illicit profits to the tune of $1.1 million by buying its stock and short-term call options using information privy to an insider.
The information pertains to positive developments in two clinical trials of its breast cancer drug candidate neratinib, which was used by Gadimian ahead of these being made public.
The perpetrator of the crime reportedly altered records of trades before submitting them to the company when it confronted him after learning of the misdeed. Subsequently, Gadimian was fired in October 2014.
We allege that Gadimian used valuable confidential information about his employer's drug trials to trade illegally and enrich himself," said Antonia Chion, associate director in the SEC's Division of Enforcement.
The release from the SEC also noted that the Attorney's Office for the District of Massachusetts brought out criminal charges against Gadimian Friday.
In the after-hours on Thursday, Puma's shares shed 4.63 percent to $63. At time of writing Friday, Puma was down 5.6 percent at $62.36.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
